2026 Annual Meeting | SP4 - Society Spotlight: Alzheimer's Association
| 03:30 PM - 03:47 PM CDT | Speaker |
Assessing the Legal and Ethical Risks of Biomarker Testing for Alzheimer’s Disease in the Clinic: Driving Towards Solutions
Jalayne Arias, JD, MA |
| 03:47 PM - 04:04 PM CDT | Speaker |
U.S. POINTER: Top-line Results and Implications
Darren R. Gitelman, MD, FAAN |
| 04:04 PM - 04:21 PM CDT | Speaker |
Evidence-based Clinical Practice Guideline: Blood Based Biomarker Guidelines
Suzanne E. Schindler, MD, PhD |
| 04:21 PM - 04:38 PM CDT | Speaker |
Evidence-based Clinical Practice Guidelines: Cognitive Assessment for Detection Guidelines
Karen Bell, MD |
| 04:38 PM - 04:55 PM CDT | Speaker |
Donanemab: Appropriate Use Recommendations and Clinical Implementation
Gil D. Rabinovici, MD, FAAN |
| 04:55 PM - 05:12 PM CDT | Speaker |
Differential Diagnosis: If It’s Not Alzheimer’s Then What’s Next? Limbic-predominant Age-related TDP-43 Encephalopathy (LATE)
S. Ahmad Sajjadi, MD, PhD, MRCP, FAAN |
| 05:12 PM - 05:29 PM CDT | Speaker |
Differential Diagnosis: If It’s Not Alzheimer’s Then What’s Next? Normal Pressure Hydrocephalus (NPH)
David T. Jones, MD |
| Vijay K. Ramanan, MD, PhD | The institution of Dr. Ramanan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Daridorexant trial for AD prevention (funded by Weston Family Foundation). The institution of Dr. Ramanan has received research support from the National Institutes of Health. The institution of Dr. Ramanan has received research support from the Mangurian Foundation for Lewy Body Disease Research. The institution of Dr. Ramanan has received research support from as part of clinical trials sponsored by the Alzheimer's Association, Eisai, the Alzheimer's Treatment and Research Institute at USC, and Transposon Therapeutics, Inc.. The institution of Dr. Ramanan has received research support from Medscape. The institution of Dr. Ramanan has received research support from Expert Perspectives in Medicine. The institution of Dr. Ramanan has received research support from Roche/ADLM. The institution of Dr. Ramanan has received research support from American College of Radiology. Dr. Ramanan has received personal compensation in the range of $500-$4,999 for serving as a Conference Speaker/Organizer (Honoraria) with AANI. Dr. Ramanan has received personal compensation in the range of $500-$4,999 for serving as a Speaker/CME Content with Clinical Care Options. |
| Jalayne Arias, JD, MA | Jalayne Arias, JD, MA has nothing to disclose. |
| Darren R. Gitelman, MD, FAAN | The institution of an immediate family member of Dr. Gitelman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Astra Zeneca. The institution of Dr. Gitelman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. The institution of Dr. Gitelman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Gitelman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. The institution of Dr. Gitelman has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. An immediate family member of Dr. Gitelman has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for UpToDate. The institution of an immediate family member of Dr. Gitelman has received research support from Pfizer. The institution of an immediate family member of Dr. Gitelman has received research support from UCB. The institution of Dr. Gitelman has received research support from Biogen. The institution of Dr. Gitelman has received research support from Eisai. The institution of Dr. Gitelman has received research support from Lilly. The institution of Dr. Gitelman has received research support from Cassava. The institution of Dr. Gitelman has received research support from Wake Forest / Alzheimer's Association / NIH. The institution of Dr. Gitelman has received research support from Davos Alzheimer's Collaborative. The institution of Dr. Gitelman has received research support from Bristol Myers Squibb. |
| Suzanne E. Schindler, MD, PhD | Dr. Schindler has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eisai. Dr. Schindler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Schindler has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novo Nordisk. The institution of Dr. Schindler has received research support from National Institute on Aging. Dr. Schindler has received personal compensation in the range of $0-$499 for serving as a Member of the Biospecimen Review Committee with National Centralized Repository for Alzheimer Disease. Dr. Schindler has a non-compensated relationship as a Board Member with Greater Missouri Alzheimer's Association that is relevant to AAN interests or activities. |
| Karen Bell, MD | Dr. Bell has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. The institution of Dr. Bell has received research support from ACTC/NIA. Dr. Bell has received personal compensation in the range of $500-$4,999 for serving as a Shareholder with Novartis. Dr. Bell has received personal compensation in the range of $500-$4,999 for serving as a Shareholder with Johnson & Johnson. Dr. Bell has received personal compensation in the range of $5,000-$9,999 for serving as a Shareholder with Pfizer. Dr. Bell has received personal compensation in the range of $0-$499 for serving as a shareholder with Baxter International. Dr. Bell has received personal compensation in the range of $0-$499 for serving as a shareholder with Takeda. Dr. Bell has received personal compensation in the range of $0-$499 for serving as a shareholder with Cardinal Health. |
| Gil D. Rabinovici, MD, FAAN | Dr. Rabinovici has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eli Lilly. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alector. Dr. Rabinovici has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Norodisk. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for C2N. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Johnson & Joihnson. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Peerview. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Medscape. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA. The institution of Dr. Rabinovici has received research support from NIH. The institution of Dr. Rabinovici has received research support from American College of Radiology. The institution of Dr. Rabinovici has received research support from Alzheimer's Association. The institution of Dr. Rabinovici has received research support from Rainwater Charitable Foundation. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Topic Chair, Course Director and teacher with AAN. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Grant reviewer with NIH. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Invited speaker with ANA. |
| David T. Jones, MD | Dr. Jones has stock in Cephlodyne Neurotechnologies, Inc.. Dr. Jones has received intellectual property interests from a discovery or technology relating to health care. |
| Sheena K. Aurora, MD | Dr. Aurora has received personal compensation for serving as an employee of Alzheimer's Association. |
| S. Ahmad Sajjadi, MD, PhD, MRCP, FAAN | Dr. Sajjadi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GUIDEPOINT. Dr. Sajjadi has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Alzheimer Research and Therapy. The institution of Dr. Sajjadi has received research support from NIH. |